DrugPatentWatch Database Preview

Teva Pharm Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA PHARM, and when can generic versions of TEVA PHARM drugs launch?

TEVA PHARM has two hundred and eighty approved drugs.

There are thirty-three US patents protecting TEVA PHARM drugs. There are thirty-four tentative approvals on TEVA PHARM drugs.

Summary for Teva Pharm

US Patents:	33
Tradenames:	234
Ingredients:	226
NDAs:	280
Patent Litigation for Teva Pharm:	See patent lawsuits for Teva Pharm
PTAB Cases with Teva Pharm as petitioner:	See PTAB cases with Teva Pharm as petitioner

Drugs and US Patents for Teva Pharm

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms	ZALEPLON	zaleplon	CAPSULE;ORAL	077239-002	Jun 6, 2008	AB	RX	No	No
Teva Pharms Usa	MITOXANTRONE HYDROCHLORIDE	mitoxantrone hydrochloride	INJECTABLE;INJECTION	077356-001	Apr 11, 2006	AP	RX	No	No
Teva Pharms	PAROXETINE HYDROCHLORIDE	paroxetine hydrochloride	TABLET;ORAL	077082-002	Jun 29, 2007		DISCN	No	No
Teva Pharms	PRAVASTATIN SODIUM	pravastatin sodium	TABLET;ORAL	077793-001	Jan 15, 2008	AB	RX	No	No
Teva Pharms Usa	LIDOCAINE	lidocaine	OINTMENT;TOPICAL	210256-001	Jan 16, 2018	AT	RX	No	No
Teva Pharms	PREDNISOLONE	prednisolone	SYRUP;ORAL	040322-001	Jan 19, 2000		DISCN	No	No
Teva Pharms Usa	ZANOSAR	streptozocin	INJECTABLE;INJECTION	050577-001	May 7, 1982		RX	Yes	Yes

Expired US Patents for Teva Pharm

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-002	Feb 12, 2002	6,342,476
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-002	Jan 27, 2017	6,446,627
Teva Pharms Usa	COPAXONE	glatiramer acetate	FOR SOLUTION;SUBCUTANEOUS	020622-001	Dec 20, 1996	6,362,161
Teva Pharm	AIRDUO RESPICLICK	fluticasone propionate; salmeterol xinafoate	POWDER;INHALATION	208799-001	Jan 27, 2017	6,446,627
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-002	Feb 12, 2002	6,939,539
Teva Pharms Usa	COPAXONE	glatiramer acetate	INJECTABLE;SUBCUTANEOUS	020622-003	Jan 28, 2014	8,367,605
Teva Pharm	ARMONAIR RESPICLICK	fluticasone propionate	POWDER;INHALATION	208798-001	Jan 27, 2017	6,446,627

Paragraph IV (Patent) Challenges for TEVA PHARM drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	for Injection	3.5 mg/vial		2016-10-26
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-01-29
	Extended-release Capsule	15 mg and 30 mg		2008-08-11
	Delayed-release Tablets	20 mg		2015-06-03
	Injection	40 mg/mL, 1 mL pre-filled syringe		2014-02-26

Premature patent expirations for TEVA PHARM

Expiration due to failure to pay maintenance fee

Patent Number	Expiration Date

International Patents for Teva Pharm Drugs

Country	Document Number	Estimated Expiration
South Korea	101507648
Japan	5820007
Israel	241912
Portugal	2189176
Uruguay	26796
South Africa	201509290
Spain	2424692

Supplementary Protection Certificates for Teva Pharm Drugs

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2014000071	Germany		PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, GESCHUETZT DURCH DAS GRUNDPATENT EP 1 506 211; REGISTRATION NO/DATE: EU/1/13/900 20140116
90027-7	Sweden		PRODUCT NAME: MONTELUKAST, R-(E)-1-1-3-2-(7-KLOR-2KINOLINYL)-ETENYL)-FENYL)-3-(2-(1-HYDROXI-1-METYLETYL)-FENYL)-PROPYL)-TIO)METYL)-CYKLOPROPANAETTIKSYRA, ELLER ETT FARMACEUTISKT GODDTAGBART SALT DAERAV, FOERETRAEDESVIS NATRIUMSALTET; NAT REG./DATE: 13944 19880111; FIRST REG.: FI EG 12766 19970825
80030	Netherlands		PRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919
2004012	Lithuania		PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-__ 1,4-DIHIDRO-8-METOKSI-7-[(4AS, 7AS)-OKTAHIDRO-6H-PIROLO[3,4-B]PIRIDIN_-6-IL]-4-OKSO-3-CHINOLINKARBOKSIRûGðTIES HIDROCHLORIDAS)
2016 00065	Denmark		PRODUCT NAME: EN KOMBINATION AF: RILPIVIRINHYDROCHLORID ELLER EN TERAPEUTISK AEKVIVALENT FORM DERAF SOM ER BESKYTTET AF GRUNDPATENTET, OG TENOFOVIRALAFENAMID, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT TENOFOVIRALAFENAMIDFUMARAT; REG. NO/DATE: EU/1/16/1112/001 20160623
90012-8	Sweden		PRODUCT NAME: TENOFOVIR ALAFENAMIDE OR A SALT OR SOLVATE THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE; REG. NO/DATE: EU/1/15/1061/001-002 20151123
C/GB03/007	United Kingdom		PRODUCT NAME: TADALAFIL AND PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF.; REGISTERED: UK EU/1/02/237/001-004 20021114

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Teva
• Teva Branded Pharm
• Teva Parenteral
• Teva Pharm
• Teva Pharms
• Teva Pharms Intl
• Teva Pharms Usa